Table 3.
List of ongoing clinical trials that evaluate the combination of PD-1/PD-L1 blockade with either cisplatin or oxaliplatin in gastric cancer.
| NCT Number | Trial phase | Patient enrollment | ICB target |
Platinum |
|---|---|---|---|---|
| NCT03675737 | Phase 3 | 1579 | PD-1 | Cisplatin or Oxaliplatin |
| NCT03221426 | Phase 3 | 1007 | PD-1 | Cisplatin or Oxaliplatin |
| NCT03615326 | Phase 3 | 732 | PD-1 | Cisplatin or Oxaliplatin |
| NCT04882241 | Phase 3 | 120 | PD-1 | Cisplatin or Oxaliplatin |
| NCT05152147 | Phase 3 | 714 | PD-1 | Cisplatin or Oxaliplatin |
| NCT03813784 | Phase 3 | 887 | PD-1 | Oxaliplatin |
| NCT03745170 | Phase 3 | 650 | PD-1 | Oxaliplatin |
| NCT02872116 | Phase 3 | 2031 | PD-1 | Oxaliplatin |
| NCT04139135 | Phase 3 | 642 | PD-1 | Oxaliplatin |
| NCT04997837 | Phase 3 | 433 | PD-1 | Oxaliplatin |
| NCT05180734 | Phase 3 | 680 | PD-1 | Oxaliplatin |
| NCT04950322 | Phase 3 | 920 | PD-L1 | Oxaliplatin |
| NCT05149807 | Phase 2/3 | 896 | PD-L1 | Oxaliplatin |
| NCT05325528 | Phase 2/3 | 40 | PD-1 | Oxaliplatin |
| NCT05002686 | Phase 2/3 | 60 | PD-1 | Oxaliplatin |
| NCT05313906 | Phase 2 | 40 | PD-1 | Cisplatin |
| NCT04249739 | Phase 2 | 93 | PD-1 | Cisplatin |
| NCT03939962 | Phase 2 | 60 | PD-1 | Oxaliplatin |
| NCT04367025 | Phase 2 | 70 | PD-1 | Oxaliplatin |
| NCT05177068 | Phase 2 | 42 | PD-1 | Oxaliplatin |
| NCT05329766 | Phase 2 | 120 | PD-1 | Oxaliplatin |
| NCT04819971 | Phase 2 | 67 | PD-1 | Oxaliplatin |
| NCT03878472 | Phase 2 | 30 | PD-1 | Oxaliplatin |
| NCT04250948 | Phase 2 | 108 | PD-1 | Oxaliplatin |
| NCT04890392 | Phase 2 | 20 | PD-1 | Oxaliplatin |
| NCT04510064 | Phase 2 | 40 | PD-1 | Oxaliplatin |
| NCT03950271 | Phase 2 | 25 | PD-1 | Oxaliplatin |
| NCT05246982 | Phase 2 | 40 | PD-1 | Oxaliplatin |
| NCT04744649 | Phase 2 | 80 | PD-1 | Oxaliplatin |
| NCT05223088 | Phase 2 | 40 | PD-1 | Oxaliplatin |
| NCT05033392 | Phase 2 | 62 | PD-1 | Oxaliplatin |
| NCT04354662 | Phase 2 | 35 | PD-1 | Oxaliplatin |
| NCT05000554 | Phase 2 | 30 | PD-1 | Oxaliplatin |
| NCT05161572 | Phase 2 | 152 | PD-1 | Oxaliplatin |
| NCT04119622 | Phase 2 | 30 | PD-1 | Oxaliplatin |
| NCT04799548 | Phase 2 | 71 | PD-1 | Oxaliplatin |
| NCT05216237 | Phase 2 | 31 | PD-1 | Oxaliplatin |
| NCT04694183 | Phase 2 | 60 | PD-1 | Oxaliplatin |
| NCT04661150 | Phase 2 | 52 | PD-L1 | Oxaliplatin |
| NCT04933227 | Phase 2 | 60 | PD-L1 | Oxaliplatin |
| NCT03399071 | Phase 2 | 40 | PD-L1 | Oxaliplatin |
| NCT03488667 | Phase 2 | 40 | PD-1 | Oxaliplatin |
| NCT03647969 | Phase 2 | 257 | PD-1 | Oxaliplatin |
| NCT04065282 | Phase 2 | 36 | PD-1 | Oxaliplatin |
| NCT02901301 | Phase 1/2 | 41 | PD-1 | Cisplatin |
| NCT03852251 | Phase 1/2 | 112 | PD-1 | Cisplatin or Oxaliplatin |